Skip to main content

Table 1 Clinical features of patients with lupus nephritis at renal biopsy

From: Dysregulated heme oxygenase-1low M2-like macrophages augment lupus nephritis via Bach1 induced by type I interferons

Characteristics of all patients with SLE (n = 19) Data
Female sex, n (%) 15 (78.9)
Age, years 31.0 ± 10.9
Duration of SLE, years 6.1 ± 7.6
Duration of LN, years 2.8 ± 5.8
Initial diagnosis of LN at renal biopsy, n (%) 13 (68.4)
ISN/RPS classification, n
 III (A) 4
 (A/C) 6 (3)a
 IV-S (A) 0
 (A/C) 3 (1)a
 -G (A) 2
 (A/C) 3
 V 1
SLEDAI score 16.0 ± 8.9
PSL, n (%) 12 (63.2)
Dosage of PSL, mg/day 15.0 ± 12.4
Concomitant immunosuppressantsb, n (%) 4 (21.1)
Urine protein, g/24 h 1.88 ± 1.93
Serum C3, mg/dl 60.1 ± 22.7 (normal range 70–129)
Serum C4, mg/dl 10.6 ± 6.9 (normal range 12–36)
Serum creatinine, mg/dl 0.65 ± 0.18 (normal range 0.48–0.82)
Anti-DNA- or anti-dsDNA antibody-positivec, n (%) 17 (89.4)
  1. Abbreviations: dsDNA Double-stranded DNA, ISN/RPS International Society of Nephrology/Renal Pathology Society, LN Lupus nephritis, SLE Systemic lupus erythematosus, SLEDAI SLE Disease Activity Index, PSL Prednisolone, C3 Complement component C3, C4 Complement component C4
  2. Data are shown as number (%) or mean ± SD
  3. aNumbers in parentheses show number of patients with class V component
  4. bConcomitant immunosuppressants included mycophenolate mofetil, cyclophosphamide, azathioprine, and tacrolimus
  5. cAnti-DNA and anti-dsDNA antibody were determined by radioimmunoassay and enzyme-linked immunosorbent assay, respectively